Lilly salutes a powerful new private-public partnership announced this week aimed at eliminating or controlling 10 neglected tropical diseases (NTDs) by the end of the decade. It's a big, audacious goal to check these diseases, which plague 1.4 billion people worldwide - most of whom are among the world's poorest.
NTDs - such as sleeping sickness, river blindness, and leprosy - are linked directly to the lack of clean water, basic sanitation, and health care. In the past, much has been accomplished against these diseases through individual players or smaller partnerships, but the complexity of viable solutions demands greater coordination, partnership, and focus.
By uniting forces, 13 pharmaceutical companies, governments, and NGOs such as the Bill & Melinda Gates Foundation and the World Bank, have pulled together the largest coordinated effort to date to fight NTDs. Together they will improve drug supply, accelerate R&D for new treatments, increase funding, and coordinate and measure their efforts.
There is no substitute for the power of effective partnership.
That's why Lilly has built active private-public partnerships to improve global health in areas where we have deep expertise, knowledge, and capabilities. The Lilly MDR-TB Partnership is working to reduce the burden of multi-drug resistant tuberculosis. The Lilly NCD Partnership is focused on reducing non-communicable diseases, specifically diabetes. Both efforts target countries with developing economies and underserved populations. And like NTDs, these health challenges are too complex to go it alone.
Watch the following video to learn more about the new partnership to fight NTDs.